Initiate Overweight in BMY with disciplined starter-then-add framework; 0.75% starter sizing, add on $64 confirmation, 1.6x ATR stop
Initiate Overweight in BMY based on asymmetric valuation (9.72x forward P/E against 34.4% operating margins, 157% FCF coverage of 3.96% dividend, beta 0.225) with a disciplined starter-then-add framework: 0.75% initial entry in $62.20-$63.70 zone, add 0.50-0.75% on confirmed close above $64.00 with volume >9M shares. Stop at $59.80 (1.6x ATR); hard invalidation below $58.44 (50 SMA). Mental stop on 2027 EPS falling below $6.00. Price targets: $68.10 first, $72-75 on Growth Portfolio re-rating. Full thesis validation at Q3 2026 earnings.
| Position | Action |
|---|---|
| Initial entry in $62.20-$63.70 zone | 0.75% position size |
| Confirmed close above $64.00 with volume >9M shares (resolves MACD bearish crossover) | Add 0.50-0.75% position size |
| Close below $58.44 (50 SMA) | Hard downgrade trigger; exit position |
| 2027 consensus EPS drops below $6.00 | Mental stop; re-evaluate thesis regardless of price |
| 10Y Treasury breaks above 4.5% decisively | Re-evaluate defensive-yield thesis |
BMY is a structurally transforming pharma giant where the growth portfolio has already reached 56% of revenues, offsetting legacy erosion, trading at a deeply discounted 9.72x forward P/E with 34.42% operating margins and a 4% dividend backed by 157% FCF coverage.
| Indicator | Value | Signal |
|---|---|---|
| 10-day EMA | $63.97 | neutral |
| 50-day SMA | $58.94 | bullish |
| 200-day SMA | $55.43 | bullish |
| MACD | 1.58 / 1.78 / hist -0.20 | bearish |
| RSI | 57.70 | neutral |
| Bollinger Upper Band | $66.78 | neutral |
| ATR | 1.73 | neutral |
| VWMA | $64.40 | bullish |
Support: 62.5 · 59.43 · 58.94 · 55.43 | Resistance: 63.97 · 65.89 · 66.78 · 68.1
BMY completed a +14.1% rally from Jul 1 close ($55.81) to Aug 12 close ($63.70), driven by a climactic move in mid-July followed by acceleration into early August. The Aug-3 intraday high of $68.10 exceeded the Bollinger upper band ($66.78) and triggered a textbook band-walk reversal, with two days of distribution following. The current pullback is occurring on declining volume (Aug-11: ~9.37M, Aug-12: ~6.02M vs. Aug-3's ~32.97M), which is structurally bullish. Price is hugging the Bollinger middle band ($63.11) after retreating from the upper band. Three scenarios weighted: bullish continuation ~55% (trigger: close > $64.00), range consolidation ~30% (chop between $62.50–$66), deeper correction ~15% (close below $62.50 targeting $59.43–$58.94). Tactical trades include trend-following long entries above $64.00 with stops at $62.20 targeting $65.90/$66.80/$68.10, and mean-reversion dip-buys at $59.50–$60.50 zone with stops at $57.90. Dividend maintained at ~$0.63 quarterly.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close above $64.00 with volume >9M shares; MACD bearish crossover resolved
Then: Add 0.50-0.75% to reach full Overweight sizing
↩ rebuts: “Bear claims Eliquis patent cliff will destroy the franchise, but growth portfolio now 56% of revenue and Q2 2026 revenue grew +5.7% YoY despite Eliquis erosion”
· concedes: Goodwill of $21.7B carries impairment risk on a 3-5 year horizon tied to acquired pipeline assets early in commercial life; Even if consensus EPS of $6.56 is 15% too high, stock still attractive at ~11x forward P/E with 4% yield and 34% operating margins
BMY's "structural transformation" is more slogan than substance—the Q2 2026 growth was a base-effect illusion, the growth portfolio competes in risky/crowded markets, the patent cliff's steepest portion lies ahead, and the forward EPS consensus is dangerously fragile, leaving the balance sheet's $45.05B debt and $39.37B goodwill/intangibles as ticking time bombs.
· concedes: Net debt reduction of $2.2B YoY and $10B repaid in Q4 2025 represent real progress on deleveraging; FCF coverage of dividends at 157% shows dividend is currently supported; The acquisitions (Karuna, Mirati, RayzeBio) contain real science and genuine optionality
→ vs conservative: MACD histogram at -0.20 is rounding error noise not momentum collapse; signal at 1.78 has barely separated. Stop at $62.20 is only $0.75 below entry, capturing rare catastrophic breakdown, not managing risk
→ vs conservative: FCF coverage ratio of 157%, beta of 0.225, and 3.96% dividend yield create thick structural floor that makes $60 breakdown scenario genuinely limited probability
→ vs conservative: Patent cliff is already priced into sub-10x forward PE; generic cliff would imply 6-7x multiple, not 9.72x. Market pricing managed transition not catastrophe
→ vs conservative: AZN merger talk provides free embedded optionality on take-private mega-merger; treating rejection as negative is short-term sentiment read not structural reality
→ vs neutral: Waiting for confirmation at $64.10 misses $1.15-$1.90 of upside per share while stop remains unchanged, compressing 7-to-1 asymmetric setup to 4-to-1
→ vs neutral: Entry zone of $62.20-$63.70 is precisely where dip is happening; price closed at $63.70 yesterday at order book levels, not theoretical
→ vs neutral: Sentiment report's 'mixed with low confidence' framing misreads split institutional coverage and missing retail data as weak thesis; underlying narrative is bullish structural shifts
→ vs neutral: Q2 2026 results already showed operating margin expansion and revenue growth despite supposed erosion headwinds, validating earnings growth thesis
Market Cap
$130.12B
PE Ratio (TTM)
14.03
Forward PE
9.72
PEG Ratio
2.29
Price to Book
5.83
EPS (TTM)
$4.54
Forward EPS
$6.56
Dividend Yield
3.96%
Beta
0.225
Revenue (TTM)
$49.19B
Gross Profit
$35.25B
EBITDA
$18.93B
Net Income
$9.28B
Profit Margin
18.87%
Operating Margin
34.42%
ROE
46.60%
ROA
10.72%
FCF
$8.11B
TTM Operating Cash Flow
~$12.78B
TTM Free Cash Flow
~$8.11B
Quarterly Dividend Payout
$1.29B
Total Assets
$87.63B
Total Liabilities
$65.32B
Stockholders' Equity
$22.32B
Total Debt
$45.05B
Net Debt
$34.40B
Cash & Equivalents
$8.72B
Current Ratio
1.53
Working Capital
$9.92B
Goodwill
$21.74B
Intangibles
$17.63B
Treasury Stock
$43.50B
Debt/Equity
201.9
Q2 2026 Revenue
$12.97B
Q2 2026 Net Income
$3.32B
Q2 2026 Diluted EPS
$1.62
Q2 2026 R&D Expense
$2.96B
52-Week High
$68.10
52-Week Low
$42.52
50-Day MA
$59.02
200-Day MA
$56.29
Strengths
Concerns
BMY trades at a statistically cheap forward PE of 9.72 relative to its 34%+ operating margins and double-digit ROE, with the market appearing to price in significant patent-cliff erosion for key drugs including Eliquis, Revlimid, and Opdivo. The company's TTM FCF of $8.11B supports both the 3.96% dividend yield and ongoing debt reduction, with net debt declining $2.2B YoY and $10.07B in long-term debt repaid in Q4 2025 alone. Whether the current pessimism is warranted depends on pipeline execution — particularly the commercialization of recently acquired assets like Karuna's Cobenfy and Mirati's Krazati — making upcoming quarterly earnings critical for validating the aggressive forward EPS estimate of $6.56.
Macro: Fed policy: 86% probability of no Fed rate cuts in 2026 (down 2.0pp week-over-week). Recession probability: US 8% (down 1.0pp), UK 20% (up 5.5pp), Japan 28% (up 4.0pp). Higher-for-longer rates are mildly supportive for high-yield defensive pharma, keeping bond proxies/dividend-paying pharma attractive on a relative basis (BMY yields ~5%+). US macro resilience is constructive for healthcare spending and earnings stability. M&A environment supportive with pent-up demand and friendly antitrust backdrop.